首页> 美国卫生研究院文献>other >CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients
【2h】

CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients

机译:结论:在不同时间点将阿德福韦地昔洛韦加入聚乙二醇干扰素α-2a对HBeAg阳性患者的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Background:The aims of this study were to compare the efficacy and safety of the addition of adefovir dipivoxil (ADV) (started at different time points) to pegylated interferon alpha-2a (PEG-INF-α2a) and PEG-INF-α2a monotherapy. This prospective, randomized study sought to evaluate the safety and efficacy of the combination of PEG-INF-α2a and ADV at different time points.120 patients were randomized into groups that received PEG-INF-α2a as monotherapy (group A) or in combination with ADV started at week 0 (group B), 12 (group C), or 24 (group D). All patients were followed for 48 weeks. Efficacy and safety analyses were performed.
机译:背景:本研究的目的是比较在聚乙二醇化干扰素α-2a(PEG-INF-α2a)和PEG-INF-α2a单一疗法中添加阿德福韦酯(ADV)(在不同时间点开始)的疗效和安全性。这项前瞻性随机研究旨在评估PEG-INF-α2a和ADV在不同时间点联合使用的安全性和有效性。将120例患者随机分为接受PEG-INF-α2a单药治疗或联合治疗的组ADV开始于第0周(B组),12周(C组)或24周(D组)。所有患者均随访48周。进行功效和安全性分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号